Monoclonal antibody isolation and characterization for COVID-19 Effort

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: Rosemarie  Mason
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2024
Award: $17,731
Funding agency: National Institute of Allergy and Infectious Diseases

We have isolated multiple SARS-CoV-2-specific monoclonal antibodies (mAbs) from SARS-CoV-2 convalescent donors from study VRC200. More than 25 mAbs isolated and characterized were neutralizing against SARS-CoV-2 with several mAbs showing cross-neutralization of multiple variants of concern (VOC) as well as SARS1, and other SARS1- and SARS2-related coronaviruses. We are drafting a manuscript to describe the isolation, characterization and high-resolution structures of 5 pan-coronavirus neutralizing mAbs. Structural analysis revealed that 2 of the mAbs disrupt/dissociate the spike trimer and target a relatively conserved epitope.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><Antibody Therapy><Antigenic Determinants><Antigens><Binding Determinants><COVID-19><COVID-19 S protein><COVID-19 antibody><COVID-19 infection><COVID-19 spike><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 virus><COVID-19 virus infection><COVID19 infection><COVID19 virus><CV-19><Cell Isolation><Cell Segregation><Cell Separation><Cell Separation Technology><Clinical Treatment Moab><CoV-2><CoV2><Coronaviridae><Coronavirus><Coronavirus Infectious Disease 2019><Development><Dissociation><Epitopes><Manuscripts><Monoclonal Antibodies><Prevention><Resolution><SARS><SARS corona virus 2><SARS coronavirus disease><SARS-CO-V2><SARS-COVID-2><SARS-CoV disease><SARS-CoV-2><SARS-CoV-2 S><SARS-CoV-2 S protein><SARS-CoV-2 antibody><SARS-CoV-2 infection><SARS-CoV-2 spike><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome coronavirus disease><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome related corona virus 2><Structure><Viral Diseases><Virus Diseases><Wuhan coronavirus><antibody against COVID-19><antibody against SARS-CoV-2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody based therapies><antibody to COVID-19><antibody to SARS-CoV-2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><antibody treatment><antibody-based therapeutics><antibody-based treatment><cell sorting><corona virus><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 antibody><coronavirus disease 2019 infection><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 virus><coronavirus infectious disease-19><develop a vaccine><develop vaccines><development of a vaccine><developmental><hCoV19><immunogen><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><mAbs><monoclonal Abs><nCoV2><neutralizing mAb><neutralizing monoclonal antibodies><resolutions><severe acute respiratory syndrome coronavirus 2 antibody><spike proteins on SARS-CoV-2><vaccine development><variants of concern><viral infection><virus infection><virus-induced disease>